Chairman & CEO, Asuragen
President and CEO, Hudson-Webber Foundation
Dean, College of Engineering, University of Washington
Professor of Bioengineering, University of Washington
Founder and Managing Partner, Frazier Healthcare Ventures
Founding Managing Partner, Forward Ventures
Co-Founder, Hunch and Founder Collective
Co-Founder and former CEO, Intellikine
|
|
Prescience International, the firm managing the Janssen Labs life sciences incubator, is hosting an in-depth look at the process of filing a biologic Investigational New Drug (IND) application, and the procedures needed to advance an early stage drug development program. Submitting an IND is a critical milestone for every biotech, regardless of whether the strategy calls for developing a drug all the way through to commercial launch or to partner with a pharmaceutical company as soon as possible. With Big Pharma and venture capital firms competing for the most promising compounds, startups are expected to demonstrate a solid plan for achieving IND acceptance. More information and online registration is here.